Guangdong Zhongsheng Pharmaceutical (002317.SZ) obtained the drug registration certificate for Emedastine Difumarate Eye Drops.

Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that the company recently received the "Drug Registration Certificate" for Emedastine Difumarate Eye Drops approved and issued by the National Medical Products Administration. This Emedastine Difumarate Eye Drops was approved for marketing under Category 4 of the chemical drug registration classification, marking that this product is deemed to have passed the consistency evaluation of chemical generic drugs. It is another eye drop product that has passed or is deemed to have passed the generic drug consistency evaluation, following the company's Azelastine Hydrochloride Eye Drops, Pranoprofen Eye Drops, Diquafosol Sodium Eye Drops, Bromfenac Sodium Eye Drops, Moxifloxacin Hydrochloride Eye Drops, Brimonidine Tartrate Eye Drops, Cyclosporine Eye Drops (III), Compound Tropicamide Eye Drops, etc., further enriching the company's product portfolio in the ophthalmic treatment field.